TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15600379

Group type: EXPERIMENTAL
Intervention: Venlafaxine (SNRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, paroxetine, sertraline, citalopram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11327200

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: tolterodine IR 2mg twice daily
Number of subjects: 19
Study: 9387134

Group type: EXPERIMENTAL
Intervention: Oral protein load (2 g/kg of protein as beefsteak)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group A (GFR 112 +/- 3 ml/min x 1.73 m2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group B (GFR 68 +/- 3.2 ml/min x 1.73 m2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group C (GFR 40.7 +/- 3.3 ml/min x 1.73 m2)
Number of subjects: 21
Study: 7968283

Group type: EXPERIMENTAL
Intervention: 600 mg of ferric ammonium citrate
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 1200 mg of ferric ammonium citrate
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Use of parasympathetic blockers
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Patients with fasting
Number of subjects: 174
Study: 2737270

Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 micrograms budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg prednisolone
Number of subjects: 0
Study: 1174258

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial milk formula (not iron-fortified)
Number of subjects: 0
Study: 31573611

Group type: EXPERIMENTAL
Intervention: Iron-casein complex
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ferrous sulfate (control)
Number of subjects: 21
Study: 28492342

Group type: EXPERIMENTAL
Intervention: Individual-level positive mental well-being and health behaviours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Individual-level social networks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neighbourhood-level measures of social networks and perceived neighbourhood quality
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Differences at the neighbourhood level
Number of subjects: 40
Study: 25310464

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (LIFE)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 113
Study: 24298767

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electroacupuncture + Acupoint Injection (EA + AI)
Number of subjects: 40
Study: 22649136

Group type: EXPERIMENTAL
Intervention: Low-dose involved-field radiation therapy (IFRT)
Number of subjects: 498

Group type: COMPARATOR
Intervention: No further therapy (control)
Number of subjects: 498
Study: 19787180

Group type: EXPERIMENTAL
Intervention: Regular physical activity during Ramadan
Number of subjects: 93

Group type: COMPARATOR
Intervention: No regular physical activity during Ramadan
Number of subjects: 93
Study: 17092974

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15302283

Group type: EXPERIMENTAL
Intervention: Group 1 (1:1 ratio of human-derived FSH:hMG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2 (3:0 ratio changed to 1:1 after GS day 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 3 (2:1 ratio increased to 3:1, 4:1, or 5:1 after GS day 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women <34 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women 34 to 40 years
Number of subjects: 0
Study: 11263519

Group type: EXPERIMENTAL
Intervention: Gradual reintroduction of isoniazid, rifampicin, ethambutol and streptomycin (Group I, n = 20)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Full-dose regimen of isoniazid, rifampicin, pyrazinamide and ethambutol (Group II, n = 25)
Number of subjects: 45
Study: 9740450

Group type: EXPERIMENTAL
Intervention: Modified PVP-free ICSI procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ICSI using polyvinylpyrrolidone (PVP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both methods (Modified ICSI and Conventional ICSI)
Number of subjects: 20
Study: 8027221

Group type: EXPERIMENTAL
Intervention: 10 mg YM175
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lower doses of YM175
Number of subjects: 79
Study: 2838715

Group type: EXPERIMENTAL
Intervention: 113mIn-indifor
Number of subjects: 88

Group type: COMPARATOR
Intervention: 99m Tc-phosphates
Number of subjects: 88
Study: 30986790

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (Dengvaxia) booster dose
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 28494809

Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t) for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 25881915

Group type: EXPERIMENTAL
Intervention: Drain insertion (group A)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No drain insertion (group B)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 193
Study: 24399727

Group type: EXPERIMENTAL
Intervention: High dose metformin (3 g daily in three divided doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 21272195

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1275
Study: 18285726

Group type: EXPERIMENTAL
Intervention: KATEX method for antigen detection in urine
Number of subjects: 132
Study: 16956341

Group type: EXPERIMENTAL
Intervention: Inosiplex, 50 mg/kg daily per os for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Inosiplex
Number of subjects: 38
Study: 12648031

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Fluvastatin (20-40 mg/day, or 40 mg twice daily)
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Lovastatin (20-40 mg/day, or 40 mg twice daily)
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Pravastatin (10-40 mg/day)
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Simvastatin (10-40 mg/day)
Number of subjects: 3887
Study: 10638663

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 50 mg/kg body weight in 5% dextrose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 50 mg/kg + rutin 5 mg/kg in 5% dextrose
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5% dextrose in water (control group)
Number of subjects: 36
Study: 9402073

Group type: COMPARATOR
Intervention: HIV vaccine intervention
Number of subjects: 48
Study: 1550667

Group type: EXPERIMENTAL
Intervention: Office blood pressure measurements (referring doctors)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Random zero office measurements
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressures
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Difference between systolic office measurements and daytime ambulatory blood pressures
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Diastolic measurements
Number of subjects: 159
Study: 3965439

Group type: EXPERIMENTAL
Intervention: Oral administration of haloperidol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous administration of haloperidol
Number of subjects: 6
Study: 29353384

Group type: EXPERIMENTAL
Intervention: Self-care training (12 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study: 28833331

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 26778661

Group type: EXPERIMENTAL
Intervention: Plyometric training + Creatine supplementation (CREATINE, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plyometric training + Placebo (PLACEBO, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CONTROL, n = 10)
Number of subjects: 30
Study: 24957544

Group type: EXPERIMENTAL
Intervention: 32-hour training course as HIV prevention peer educators
Number of subjects: 182

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 182
Study: 22414319

Group type: EXPERIMENTAL
Intervention: 12 week exercise programme of 12 × 60 minutes of preferred intensity aerobic exercise with motivational coaching and support
Number of subjects: 158

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 158
Study: 20589253

Group type: EXPERIMENTAL
Intervention: Dental plaque-free samples (GI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dental plaque-covered samples (GII)
Number of subjects: 13
Study: 17888803

Group type: EXPERIMENTAL
Intervention: CALM intervention (education and behavioral activation delivered by anxiety clinical specialists, with options for cognitive-behavioral therapy, antianxiety medications, or both)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Usual care from primary care clinician
Number of subjects: 1040
Study: 15142360

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) plus slow-release triiodothyronine (T3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyroxine (T4) only
Number of subjects: 0
Study: 11784215

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 9660534

Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone (250 mg i.v. twice daily)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Granisetron alone (3 mg i.v. over 30 s)
Number of subjects: 308
Study: 8704424

Group type: EXPERIMENTAL
Intervention: Zhong Feng I oral liquor (acute stage), Zhong Feng II oral liquor (convalescent stage) and Western medicine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 120
Study: 2515723

Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg per day
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Tocopherol 2000 IU per day
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Deprenyl plus Tocopherol
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 649844

Group type: EXPERIMENTAL
Intervention: 80 dB tone with active response
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 80 dB tone with passive escape contingency
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inescapable tone
Number of subjects: 96

Group type: COMPARATOR
Intervention: No noise (control group)
Number of subjects: 96
Study: 31830798

Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known, a values‐neutral, educational, computer‐based decision aid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard living will + brochure
Number of subjects: 200
Study: 30922751

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 114

Group type: COMPARATOR
Intervention: Attention-control group (light resistance training)
Number of subjects: 114
Study: 28835364

Group type: EXPERIMENTAL
Intervention: Home-based growth monitoring (HBGM)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Community-based growth monitoring with nutritional supplementation (CBGM+NS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 547
Study: 26262764

Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff (TSC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cylindrical-shaped cuff (CSC)
Number of subjects: 98
Study: 24791510

Group type: EXPERIMENTAL
Intervention: Combination therapy of small needle knife and Daqinjiu Tang
Number of subjects: 118

Group type: COMPARATOR
Intervention: Small needle knife
Number of subjects: 118
Study: 21330911

Group type: EXPERIMENTAL
Intervention: ALVAC with Remune
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ALVAC alone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ALVAC with Remune and ALVAC alone (combined vaccine groups)
Number of subjects: 52
Study: 19011261

Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 131

Group type: COMPARATOR
Intervention: 21% air
Number of subjects: 131
Study: 16077745

Group type: EXPERIMENTAL
Intervention: New enteral formula low in carbohydrates and high in monounsaturated fatty acids (MUFAs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard enteral formula (control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: New enteral formula low in carbohydrates and high in MUFAs
Number of subjects: 78
Study: 11833404

Group type: EXPERIMENTAL
Intervention: Grip strength measured via a dynamometer and pinch strength via a pinch meter.
Number of subjects: 51
Study: 10577644

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7560619

Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Directional Atherectomy
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Peripheral Vascular Complications
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Patients with Peripheral Vascular Complications
Number of subjects: 1012
Study: 2140432

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: TENS plus exercises
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sham TENS plus exercises
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonexercise groups
Number of subjects: 145
Study: 7004956

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium suspension
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30353603

Group type: EXPERIMENTAL
Intervention: Musical training (weekly 45-min lessons for 52 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 60
Study: 28747269

Group type: EXPERIMENTAL
Intervention: 4HIIT (4×4min bouts at 85-95%HRpeak, 3×/week)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MICT (30min at 60-70%HRpeak, 5×/week)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1HIIT (1×4min bout at 85-95%HRpeak, 3×/week)
Number of subjects: 56
Study: 26479077

Group type: EXPERIMENTAL
Intervention: Health risk assessment (HRA) and counselling over a 2-year period.
Number of subjects: 2284
Study: 24036724

Group type: EXPERIMENTAL
Intervention: CT scan (group 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No CT scan (group 2)
Number of subjects: 76
Study: 21225098

Group type: EXPERIMENTAL
Intervention: Oral dabigatran 220 mg once-daily
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once-daily
Number of subjects: 2055
Study: 19137352

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 33
Study: 17356145

Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock-wave therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-energy extracorporeal shock-wave therapy
Number of subjects: 80
Study: 15359161

Group type: EXPERIMENTAL
Intervention: Wide diameter implants (5.0 and 6.0 mm)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard diameter implants (3.75 and 4.0 mm)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Torque driver used to tighten screws
Number of subjects: 106
Study: 11123735

Group type: EXPERIMENTAL
Intervention: Clonidine, 4 microg x kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam, 0.4 mg x kg(‐1)
Number of subjects: 60
Study: 9720821

Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg)
Number of subjects: 12
Study: 7989502

Group type: EXPERIMENTAL
Intervention: Onapristone 5 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Onapristone 15 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Onapristone 50 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Post-treatment (after discontinuation of onapristone)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Luteal phase post-treatment
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cortisol concentrations
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Serious side effects
Number of subjects: 7
Study: 2658875

Group type: EXPERIMENTAL
Intervention: Amino-hydroxypropylidene bisphosphonate (APD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 5579489

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of anticholinergic drugs over four weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of anticholinergic drugs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stable levodopa therapy with anticholinergic drugs
Number of subjects: 34
Study: 29747321

Group type: EXPERIMENTAL
Intervention: Lower risk group (SYNTAX score≤22)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Intermediate risk group (SYNTAX score 23‐32)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Higher risk group (SYNTAX score≥33)
Number of subjects: 2348
Study: 28264826

Group type: EXPERIMENTAL
Intervention: Computer-determined dosage of insulin (CDD) using the STAR-GRYPHON model
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bedside titration: insulin dose determined by medical staff
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care: insulin dose and frequency of blood glucose testing determined by medical staff
Number of subjects: 138
Study: 25742886

Group type: EXPERIMENTAL
Intervention: Physioneal
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dianeal
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 23206182

Group type: EXPERIMENTAL
Intervention: Rivastigmine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine in combination therapy
Number of subjects: 0
Study: 21244204

Group type: EXPERIMENTAL
Intervention: Coping skills group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18489804

Group type: EXPERIMENTAL
Intervention: Walking exercise group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nutrition education control group
Number of subjects: 26
Study: 16572592

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Number of subjects: 0
Study: 12736476

Group type: EXPERIMENTAL
Intervention: Anteroseptal myocardial infarction (MI) group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MI group
Number of subjects: 61
Study: 10540063

Group type: EXPERIMENTAL
Intervention: Latex balloon pressure controller
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tracheal tube cuff without controller
Number of subjects: 0
Study: 8569424

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally each evening for 1 week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 8
Study: 1910730

Group type: EXPERIMENTAL
Intervention: Perioperative and postoperative steroid use
Number of subjects: 49
Study: 6121581

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 50
Study: 31519527

Group type: EXPERIMENTAL
Intervention: Psychosocial variables (including religiosity, knowledge regarding blood donation process, overall quality of life, blood donation of peers, sociodemographic variables, fear of blood, injections, and fainting)
Number of subjects: 1055
Study: 28447237

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study: 26422096

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study: 23319135

Group type: EXPERIMENTAL
Intervention: Clinofibrate 200mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinofibrate 400mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinofibrate 600mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinofibrate (all doses)
Number of subjects: 0
Study: 21881066

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based HAART
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor-based HAART (without PI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (HIV-negative participants)
Number of subjects: 40
Study: 19118720

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 17446306

Group type: EXPERIMENTAL
Intervention: Pregabalin (200 mg tid for 3 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15132449

Group type: EXPERIMENTAL
Intervention: Bonding with Equalized Specific Thickness (BEST) technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transfer Optimized Positioning (TOP) method
Number of subjects: 41
Study: 11824173

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 628

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 628